 Akers Biosciences, Inc. the Company AKER, a developer of rapid health information technologies, announced today that on December 10, 2019, it received notice from the Hearings Advisor of the Nasdaq Office of General Counsel that the Company successfully regained compliance with the minimum bid price requirements set forth under Nasdaq Listing Rule 5550a2 for continued listing on the Nasdaq Capital Market and that the Company is in compliance with all other applicable listing standards. 